Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8906827 | 0.94 | ALDH1A1 (0.38) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL9196383 | 0.92 | LMNA (0.38) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL22661239 | 0.91 | SMN1; SMN2 (0.40) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL9188694 | 0.87 | LMNA (0.40) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL10455405 | 0.87 | LMNA (0.40) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL3057308 | 0.86 | LMNA (0.43) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL22645203 | 0.86 | LMNA (0.47) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL709354 | 0.85 | LMNA (0.39) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 | |
| SCHEMBL11279946 | 0.85 | POLB (0.39) | MAPTLMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL11285322 | 0.84 | LMNA (0.46) | ALDH1A1HPGDUSP2SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023117667-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOISOPHTHALIC BISAMIDES | BRACCO IMAGING SPA (IT) | 2023-06-29 | — | — | WO | disclosed |
| EP-3580199-B1 | METHOD FOR THE ONE-POT PRODUCTION OF ORGANO-IODINATED COMPOUNDS | GUERBET SA (FR) | 2023-04-05 | — | — | EP | disclosed |
| CN-110267937-B | Method for producing organic iodinated compound by one-pot method | 法国加柏公司 | 2022-09-23 | — | — | CN | disclosed |
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
| EP-2365963-B1 | PROCESS FOR THE PREPARATION OF IODINATED CONTRAST AGENT | BRACCO IMAGING SPA (IT) | 2017-06-28 | — | — | EP | disclosed |
| US-8624061-B2 | Process for the preparation of iodinated contrast agent | BRACCO IMAGING S.P.A. (IT) | 2014-01-07 | — | — | US | disclosed |
| EP-2200971-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2013-04-24 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| EP-0619744-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT MEDICAL, INC. (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994005337-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT MEDICAL, INC. (US) | 1994-03-17 | — | — | WO | disclosed |
| WO-1993010825-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT MEDICAL, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| US-5191120-A | Process for preparing nonionic X-ray contrast agents | MALLINCKRODT MEDICAL, INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0504266-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5075502-A | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1991-12-24 | — | — | US | disclosed |
| WO-1991009007-A2 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1991-06-27 | — | — | WO | disclosed |
| US-4352788-A | ARTERIES | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1982-10-05 | — | — | US | disclosed |
| US-4348377-A | RADIOPACITY | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1982-09-07 | — | — | US | disclosed |
| US-4139605-A | A, W-BIS(5-(DIHYDROXYALKYL)AMINOCARBONYL-3-HYDROXYACYLAMINO-2,4,6 -TRIIODOBENZOYLAMINO)-OXAALKANE | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | TPO, NISCH, PPIP5K2 | ALDH1A1 2138/4885HPGD 1759/4885USP2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.